STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMAX
  4. [Form 4] IMAX CORP Insider Trading Activity

IMAX (IMAX) CEO completes 10b5-1 plan with 8,943-share sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IMAX CORP Chief Executive Officer Richard Gelfond reported an option exercise and related share sale. On April 27, 2026, he converted 8,943 stock options into common shares at $31.40 per share, then sold 8,943 common shares at an average price of $37.3269 per share.

The transactions were executed pursuant to a Rule 10b5-1 plan dated December 9, 2025, and sales under that plan are now complete. Following these transactions, Gelfond holds 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,332,411 stock options, 231,562 restricted share units and 765,002 common shares, respectively.

Positive

  • None.

Negative

  • None.
Insider GELFOND RICHARD L
Role Chief Executive Officer
Sold 8,943 shs ($334K)
Type Security Shares Price Value
Conversion stock options (to buy) 8,943 $31.40 $281K
Conversion common shares 8,943 $31.40 $281K
Sale common shares 8,943 $37.3269 $334K
holding common shares (opening balance) -- -- --
Holdings After Transaction: stock options (to buy) — 1,332,411 shares (Direct, null); common shares — 773,945 shares (Direct, null); common shares (opening balance) — 765,002 shares (Direct, null)
Footnotes (1)
  1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025. Effective April 27, 2026, the sales under the 10b5-1 plan are complete. These options were issued in 2016 and are set to expire on June 7, 2026. The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,332,411, 231,562 and 765,002, respectively.
Shares sold 8,943 shares Common shares sold on April 27, 2026
Sale price per share $37.3269 per share Average price for 8,943 common shares sold
Option exercise price $31.40 per share Exercise price for 8,943 stock options converted to common shares
Common shares held after 765,002 shares Common share balance following April 27, 2026 transactions
Outstanding stock options 1,332,411 options Aggregate remaining outstanding options after transactions
Outstanding RSUs 231,562 RSUs Aggregate remaining restricted share units after transactions
Option expiration date June 7, 2026 Expiration date of the 2016-issued stock options
Rule 10b5-1 Plan regulatory
"pursuant to a 10b5-1 Plan dated December 9, 2025"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Conversion of derivative security financial
"transaction_code_description: Conversion of derivative security"
stock options financial
"These options were issued in 2016 and are set to expire on June 7, 2026"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
restricted share unit financial
"aggregate remaining outstanding option, restricted share unit and common share balances"
A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GELFOND RICHARD L
(Last)(First)(Middle)
902 BROADWAY
20TH FLOOR
(Street)
NEW YORK NEW YORK 10010-6002
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IMAX CORP [ IMAX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
common shares (opening balance)765,002D
common shares04/27/2026C8,943(1)A$31.4773,945D
common shares04/27/2026S8,943D$37.3269765,002D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
stock options (to buy)(2)$31.404/27/2026C8,943 (3)06/07/2026common shares8,943$31.41,332,411(4)D
Explanation of Responses:
1. Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025. Effective April 27, 2026, the sales under the 10b5-1 plan are complete.
2. These options were issued in 2016 and are set to expire on June 7, 2026.
3. The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.
4. This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,332,411, 231,562 and 765,002, respectively.
Remarks:
/s/ Richard L. Gelfond04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did IMAX (IMAX) CEO Richard Gelfond report in this Form 4?

IMAX CEO Richard Gelfond reported exercising stock options for 8,943 common shares and selling 8,943 common shares. The transactions occurred on April 27, 2026, and were executed under a Rule 10b5-1 trading plan dated December 9, 2025, which has now completed its sales.

How many IMAX (IMAX) shares did Richard Gelfond sell and at what price?

Richard Gelfond sold 8,943 IMAX common shares at an average price of $37.3269 per share. These were open-market or private transactions on April 27, 2026, immediately after converting stock options into the same number of common shares at an exercise price of $31.40.

Were the IMAX (IMAX) CEO’s transactions made under a Rule 10b5-1 plan?

Yes. The filing states the option conversion and related share sales occurred pursuant to a Rule 10b5-1 plan dated December 9, 2025. It also notes that, effective April 27, 2026, the sales under this 10b5-1 trading plan are complete, indicating a pre-arranged program.

What IMAX (IMAX) holdings does Richard Gelfond report after these transactions?

After these transactions, Richard Gelfond reports holding 765,002 IMAX common shares. Footnote disclosure adds that his aggregate remaining outstanding balances are 1,332,411 stock options, 231,562 restricted share units and 765,002 common shares, giving investors a snapshot of his post-transaction equity exposure.

What stock options did the IMAX (IMAX) CEO exercise and when do they expire?

Gelfond exercised stock options covering 8,943 IMAX common shares at an exercise price of $31.40 per share. Footnotes explain these options were issued in 2016, became exercisable in three installments during 2016, and are set to expire on June 7, 2026 if not exercised.

How many IMAX (IMAX) options and RSUs remain outstanding for Richard Gelfond?

Footnotes state that following these transactions, Gelfond’s aggregate remaining outstanding balances include 1,332,411 stock options and 231,562 restricted share units. This is in addition to 765,002 common shares, providing a breakdown of his remaining derivative and share-based compensation exposure in IMAX.